Bioventus Inc.
BVS
$6.56
$0.010.15%
NASDAQ
| 06/28/2025 | 03/29/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.20% | -19.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.20% | -19.37% | |||
| Cost of Revenue | 11.64% | -19.94% | |||
| Gross Profit | 22.92% | -19.09% | |||
| SG&A Expenses | 7.65% | -15.08% | |||
| Depreciation & Amortization | -9.67% | -9.90% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.73% | -16.58% | |||
| Operating Income | 269.64% | -55.24% | |||
| Income Before Tax | 401.81% | -1,572.84% | |||
| Income Tax Expenses | 1,195.79% | -117.27% | |||
| Earnings from Continuing Operations | 379.11% | -944.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -364.67% | 322.84% | |||
| Net Income | 382.86% | -1,590.38% | |||
| EBIT | 269.64% | -55.24% | |||
| EBITDA | 80.73% | 5.93% | |||
| EPS Basic | 381.20% | -1,562.50% | |||
| Normalized Basic EPS | 432.38% | -160.87% | |||
| EPS Diluted | 375.69% | -1,562.50% | |||
| Normalized Diluted EPS | 422.38% | -160.87% | |||
| Average Basic Shares Outstanding | 0.74% | 0.85% | |||
| Average Diluted Shares Outstanding | 3.83% | 0.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||